Jason Aryeh Purchases 8,971 Shares of Orchestra BioMed (NASDAQ:OBIO) Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Jason Aryeh bought 8,971 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $3.90 per share, with a total value of $34,986.90. Following the completion of the acquisition, the director owned 117,453 shares in the company, valued at $458,066.70. This represents a 8.27% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jason Aryeh also recently made the following trade(s):

• On Monday, May 18th, Jason Aryeh purchased 665 shares of Orchestra BioMed stock. The stock was bought at an average cost of $3.75 per share, for a total transaction of $2,493.75.

Orchestra BioMed Stock Performance

Shares of NASDAQ:OBIO opened at $3.98 on Thursday. The business’s fifty day moving average price is $4.26 and its two-hundred day moving average price is $4.27. Orchestra BioMed Holdings, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $5.42. The stock has a market capitalization of $238.33 million, a price-to-earnings ratio of -4.10 and a beta of 0.52. The company has a debt-to-equity ratio of 0.35, a current ratio of 7.03 and a quick ratio of 7.01.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.92 million. As a group, analysts predict that Orchestra BioMed Holdings, Inc. will post -1.54 EPS for the current fiscal year.

Trending Headlines about Orchestra BioMed

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: Multiple insiders bought shares, including Director Eric Fain’s purchase of 20,000 shares and additional buying by insider David Hochman and Director Jason Aryeh. Insider accumulation is often viewed as a signal that management believes the stock is undervalued. SEC filing for Eric Fain purchase
• Positive Sentiment: HC Wainwright reiterated a Buy rating on OBIO and maintained a $10 price target while slightly lifting some earnings estimates, reinforcing Wall Street’s view that the stock has meaningful upside from current levels. Benzinga report
• Positive Sentiment: Orchestra BioMed said management will participate in the Jefferies Global Healthcare Conference, which could increase visibility with investors and potential strategic partners. Conference announcement
• Neutral Sentiment: B. Riley Financial lowered its price target to $10 from $12 but kept a Buy rating, so the message was mixed rather than outright negative. Benzinga report

Analyst Upgrades and Downgrades

OBIO has been the topic of a number of recent analyst reports. Weiss Ratings lowered shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday, March 12th. Wall Street Zen downgraded Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. B. Riley Financial decreased their price target on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Barclays raised their price target on Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $13.60.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in OBIO. China Universal Asset Management Co. Ltd. acquired a new stake in Orchestra BioMed in the 4th quarter valued at about $38,000. Virtu Financial LLC acquired a new position in shares of Orchestra BioMed during the fourth quarter worth approximately $57,000. Creative Planning bought a new stake in shares of Orchestra BioMed during the second quarter valued at approximately $40,000. XTX Topco Ltd bought a new stake in shares of Orchestra BioMed during the second quarter valued at approximately $45,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Orchestra BioMed in the fourth quarter valued at approximately $76,000. Institutional investors and hedge funds own 53.20% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.